[go: up one dir, main page]

MX2010007461A - Nuevas vacunas contra multiples subtipos del virus del dengue. - Google Patents

Nuevas vacunas contra multiples subtipos del virus del dengue.

Info

Publication number
MX2010007461A
MX2010007461A MX2010007461A MX2010007461A MX2010007461A MX 2010007461 A MX2010007461 A MX 2010007461A MX 2010007461 A MX2010007461 A MX 2010007461A MX 2010007461 A MX2010007461 A MX 2010007461A MX 2010007461 A MX2010007461 A MX 2010007461A
Authority
MX
Mexico
Prior art keywords
dengue virus
immune response
dna plasmid
vaccines against
against multiple
Prior art date
Application number
MX2010007461A
Other languages
English (en)
Inventor
Mathura P Ramanathan
Niranjan Y Sardesai
Original Assignee
VGX Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VGX Pharmaceuticals LLC filed Critical VGX Pharmaceuticals LLC
Publication of MX2010007461A publication Critical patent/MX2010007461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con construcciones de ácidos nucleicos capaces de expresar un polipéptido que provoca una respuesta inmunitaria en un mamífero contra más de un subtipo de virus de dengue y métodos de uso del mismo. Además, hay vacunas de plásmidos de ADN capaces de generar en un mamífero una repuesta inmune contra una pluralidad de subtipos de virus de dengue, que comprenden un plásmido de ADN y un excipiente farmacéuticamente aceptable y métodos de uso de los mismos. El plásmido de ADN es capaz de expresar un antígeno de dengue consenso en una célula del mamífero en una cantidad efectiva para provocar una respuesta inmune en el mamífero.
MX2010007461A 2008-01-11 2009-01-12 Nuevas vacunas contra multiples subtipos del virus del dengue. MX2010007461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2049008P 2008-01-11 2008-01-11
PCT/US2009/030776 WO2009099716A1 (en) 2008-01-11 2009-01-12 Novel vaccines against multiple subtypes of dengue virus

Publications (1)

Publication Number Publication Date
MX2010007461A true MX2010007461A (es) 2010-10-20

Family

ID=40952413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007461A MX2010007461A (es) 2008-01-11 2009-01-12 Nuevas vacunas contra multiples subtipos del virus del dengue.

Country Status (11)

Country Link
US (1) US8835620B2 (es)
EP (1) EP2234624B1 (es)
JP (1) JP5788676B2 (es)
KR (1) KR101686942B1 (es)
CN (1) CN101909635B (es)
AU (1) AU2009210624A1 (es)
CA (1) CA2708668C (es)
ES (1) ES2685435T3 (es)
MX (1) MX2010007461A (es)
WO (1) WO2009099716A1 (es)
ZA (1) ZA201004688B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426827B1 (en) * 2006-11-06 2019-10-01 Microvax, Llc Dengue hemorrhagic fever virus vaccine
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2550298B1 (en) 2010-03-23 2015-07-15 The Regents of The University of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
CN103118701B (zh) * 2010-05-14 2017-10-24 百深公司 Ospa嵌合体及其在疫苗中的用途
WO2011146933A2 (en) 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use
EP3431100B1 (en) 2010-09-14 2021-09-08 University of Pittsburgh- Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
EP2621525A4 (en) * 2010-10-01 2015-01-14 Univ Rochester Flavivirus DOMAIN III VACCINE
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
MX343830B (es) 2011-02-11 2016-11-24 Univ Pennsylvania Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
JP6407028B2 (ja) * 2011-12-12 2018-10-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
HK1220905A1 (zh) 2013-03-12 2017-05-19 The Trustees Of The University Of Pennsylvania 用於人乳头状瘤病毒的改进疫苗及其使用方法
CA2906082A1 (en) 2013-03-15 2014-09-18 Inovio Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
JP6457481B2 (ja) * 2013-03-15 2019-01-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア デングウイルスの複数のサブタイプに対する新規ワクチン
ITRM20130458A1 (it) 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
NO340722B1 (no) * 2014-06-27 2017-06-06 Norwegian Institute For Agricultural & Environmental Res Transgene planter som uttrykker et rekombinant tetravalent kimært denguevirusantigen for å fremstille effektive vaksiner avledet derfra, samt transgent plastid, plantecelle og frø, rekombinant DNA molekyl, vektor, fremgangsmåter for fremstilling og anvendelse derav
US11459619B2 (en) 2016-02-08 2022-10-04 The Johns Hopkins University Handheld nucleic acid-based assay for rapid identification
WO2017142831A1 (en) * 2016-02-16 2017-08-24 Albert Einstein College Of Medicine, Inc. Dengue virus glycoprotein e diii variants and uses thereof
CA3015792A1 (en) 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
JP6518971B2 (ja) * 2017-05-12 2019-05-29 株式会社ベックス エレクトロポレーター用電源
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
CN115990249B (zh) * 2022-10-10 2025-07-25 中国人民解放军陆军军医大学 一种登革四价dna疫苗及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
CA2224724C (en) 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
CA2330211A1 (en) * 1998-06-08 1999-12-16 Karel Petrak Formulations for electroporation
WO2000045823A1 (en) * 1999-02-08 2000-08-10 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
JP4472250B2 (ja) * 2000-10-04 2010-06-02 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 高発現可能遺伝子
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
NZ535690A (en) * 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
US7238522B2 (en) 2003-05-30 2007-07-03 Advisys, Inc. Devices and methods for biomaterial production
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
WO2007034507A2 (en) 2005-09-20 2007-03-29 International Centre For Genetic Engineering And Biotechnology Tetravalent dengue specific domain iii based chimeric recombinant protein
EP2153260B1 (en) 2007-05-23 2017-01-25 VGXI, Inc. Composition comprising high concentration of biologically active molecules and processes for preparing the same
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Also Published As

Publication number Publication date
CN101909635B (zh) 2014-09-17
US8835620B2 (en) 2014-09-16
WO2009099716A1 (en) 2009-08-13
US20100291144A1 (en) 2010-11-18
KR101686942B1 (ko) 2016-12-28
EP2234624A4 (en) 2013-02-13
CA2708668A1 (en) 2009-08-13
EP2234624B1 (en) 2018-06-20
ES2685435T3 (es) 2018-10-09
ZA201004688B (en) 2011-04-28
EP2234624A1 (en) 2010-10-06
CN101909635A (zh) 2010-12-08
JP5788676B2 (ja) 2015-10-07
KR20100103677A (ko) 2010-09-27
AU2009210624A1 (en) 2009-08-13
JP2011509659A (ja) 2011-03-31
WO2009099716A9 (en) 2009-10-01
WO2009099716A4 (en) 2009-11-19
CA2708668C (en) 2019-03-05

Similar Documents

Publication Publication Date Title
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
MX2018010291A (es) Vacunas novedosas contra el virus de zika.
Li et al. A comprehensive review of the global efforts on COVID-19 vaccine development
Liu Immunologic basis of vaccine vectors
US20220347287A1 (en) Universal vaccines against immunogens of pathogenic organisms that provide organism-specific and cross-group protection
de Vries et al. Viral vector-based influenza vaccines
Magini et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge
MX339241B (es) Vacunas novedosas contra sub-tipos multiples de virus de influenza.
WO2011163628A3 (en) Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof
MX377804B (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
EA201591213A1 (ru) Вакцины против вируса гепатита b
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
PE20140845A1 (es) Formulaciones parenterales de vacunas contra los norovirus
WO2010044919A3 (en) Smallpox dna vaccine and the antigens therein that elicit an immune response
AR110632A1 (es) Vectores del adenovirus canino
EA201170965A1 (ru) Усовершенствованные вакцины вируса человеческой папилломы и способы их использования
CO6140071A2 (es) Poxvirus de mapache que expresa glicoproteinas de la rabia
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
Dora et al. An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
MX338052B (es) Vectores de parapoxvirus que contienen el antigeno del virus de la rabia.
AR082281A1 (es) Vectores de parapoxvirus
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
Szurgot et al. Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform
MX365656B (es) Nuevas vacunas contra multiples subtipos del virus del dengue.

Legal Events

Date Code Title Description
FG Grant or registration